反应详情

To a solution of (2S)-2-[(tert-butoxycarbonyl)amino]-3-[4-(2-tert-butyl-1,1-dioxido-3-oxoisothiazolidin-5-yl)phenyl]propanoic acid (12 mg, 0.035 mmol) in N,N-dimethylformamide (1.0 mL,) was added N,N-diisopropylethylamine (0.018 mL, 0.10 mmol) and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (16 mg, 0.042 mmol) and premixed for 5 minutes. Methyl 2-(4-aminobutoxy)-6-hydroxybenzoate hydrochloride (12 mg, 0.042 mmol) was added and the mixture was stirred for 2 h. The product was purified by preparative LCMS to afford the desired product (4.0 mg, 20%). 1H NMR (500 MHz, CD3OD): δ 7.43–7.45 (m, 2H), 7.35–7.36 (m, 2H), 7.27(t, J=8.3 Hz), 6.49–6.53 (m, 2H), 5.12–5.17 (m, 1H), 4.55–4.59 (m, 1H), 3.96–3.99 (m, 2H), 3.90 (s, 3H), 2.89–3.89 (m, 4H), 1.95 (s, 3H), 1.64–1.68 (m, 2H), 1.57–1.61 (m, 2H); LCMS found for C26H32N3O9S (M+H)+: m/z=562.2.

1. additionpremixed for 5 minutes
2. customThe product was purified by preparative LCMS